nach oben

Erschienen in:

27.09.2022 | Observational Research

Bibliometric and altmetric analyses of publication activity in the field of idiopathic inflammatory myopathy in 2011–2021 based on web of science core collection databases

verfasst von: Mengxiang Li, Feng Yin, Youxian He, Xue Zhang, Hao Yu, Qiuyu Yang, Xintong Xie, Guangliang Wei, Huidong Chen, Chengsong He, Yue He, Jie Chen

Erschienen in: Rheumatology International | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Idiopathic inflammatory myopathy is a multisystem autoimmune condition characterized by muscle inflammation (myositis) and interstitial lung disease (ILD). Bibliometric analysis and altmetric analysis are effective methods of evaluating academic productivity and measuring the influence of publications. The purpose of this study is to analyze the research productivity and influence of idiopathic inflammatory myopathy articles using bibliometric analysis and altmetric analysis. Data from articles published between 2011 and 2021 were obtained from the Web of Science. Altmetric attention scores and Mendeley reader counts of the articles were obtained from altmetric evaluations. In the study, 2060 articles related to idiopathic inflammatory myopathy were screened out showing an increasing trend in general. In terms of the origin countries of articles, the United States (n = 467, 22.67%) ranked first. Johns Hopkins University has the largest number of institutions (n = 113). The journals regarding idiopathic inflammatory myopathy and Rheumatology (n = 87) published the most articles. The most cited article was published by Mammen et al. and was related to autoantibodies. Dermatomyositis, polymyositis and other research hotspots were represented by keywords. The results of the altmetric analysis showed that citations, impact factors and h-index were significantly correlated with Altmetric Attention Scores and Mendeley Readers Count (P < 0.05). In summary, bibliometric analysis summarizes the current status of idiopathic inflammatory myopathy research and helps to understand the development of idiopathic inflammatory myopathy in the field between 2011 and 2021. Altmetric analysis was used to evaluate the academic and social influence of articles from the novel perspective of internet attention.

Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V et al (2022) British society for rheumatology guideline on management of paediatric adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology. https://doi.org/10.1093/rheumatology/keac115CrossRefPubMedPubMedCentral

McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302. https://doi.org/10.1038/nrrheum.2018.56CrossRefPubMed

Vencovsky J, Alexanderson H, Lundberg IE (2019) Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 45(4):569–581. https://doi.org/10.1016/j.rdc.2019.07.006CrossRefPubMed

Tanboon J, Uruha A, Stenzel W, Nishino I (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33(5):590–603. https://doi.org/10.1097/WCO.0000000000000855CrossRefPubMed

Bolko L, Jiang W, Tawara N, Landon Cardinal O, Anquetil C, Benveniste O et al (2021) The role of interferons type I, II and III in myositis: a review. Brain Pathol 31:3. https://doi.org/10.1111/bpa.12955CrossRef

Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269–278. https://doi.org/10.1038/nrrheum.2018.41CrossRefPubMed

Koo M (2021) Systemic lupus erythematosus research: a bibliometric analysis over a 50-year period. Int J Environ Res Public Health 18(13):7095. https://doi.org/10.3390/ijerph18137095CrossRefPubMedPubMedCentral

Wang S-Q, Gao Y-Q, Zhang C, Xie Y-J, Wang J-X, Xu F-Y (2020) A bibliometric analysis using citespace of publications from 1999 to 2018 on patient rehabilitation after total knee arthroplasty. Med Sci Monit. https://doi.org/10.1265/MSM.920795CrossRefPubMedPubMedCentral

Wu L-Z, Weng Y-Q, Ling Y-X, Zhou S-J, Ding X-K, Wu S-Q et al (2021) A web of science based scientometric analysis about mammalian target of rapamycin signaling pathway in kidney disease from 1986 to 2020. Transl Androl Urol 10(3):1006–1017. https://doi.org/10.2103/tau-20-1469CrossRefPubMedPubMedCentral

10.

Chan KIP, Ignacio KHD, Omar AT II, Khu KJO (2022) Top 100 most cited neurologic and neurosurgical articles on covid-19: a bibliometric analysis. World Neurosurg 157:E137–E147. https://doi.org/10.1016/j.wneu.2021.09.118CrossRefPubMed

11.

Viani GA, Gouveia AG, Jacinto AA, Moraes FY (2021) Stereotactic body radiotherapy for prostate cancer where, when, and who? a bibliometric analysis. Am J Clin Oncol 44(11):553–558. https://doi.org/10.1097/COC.0000000000000869CrossRefPubMed

12.

Xing D, Zhao Y, Dong S, Lin J (2018) Global research trends in stem cells for osteoarthritis: a bibliometric and visualized study. Int J Rheum Dis 21(7):1372–1384. https://doi.org/10.1111/1756-185X.13327CrossRefPubMed

13.

Akyol A, Kocyigit BF (2021) Ankylosing spondylitis rehabilitation publications and the global productivity: a web of science-based bibliometric analysis (2000–2019). Rheumatol Int 41(11):2007–2014. https://doi.org/10.1007/s00296-021-04836-0CrossRefPubMed

14.

Akyol A, Kocyigit BF (2021) Publication activity in the field of Sjogren’s syndrome: a ten-year web of science based analysis. Rheumatol Int 41(4):763–769. https://doi.org/10.1007/s00296-020-04714-1CrossRefPubMed

15.

Robinson DBT, Powell AGMT, Waterman J, Hopkins L, James OP, Egan RJ et al (2021) Predictive value of altmetric score on citation rates and bibliometric impact. Bjs Open 5:1. https://doi.org/10.1093/bjsopen/zraa039CrossRef

16.

Kocyigit BF, Akyol A (2021) Bibliometric and altmetric analyses of publication activity in the field of Behcet’s disease in 2010–2019. J Korean Med Sci 36:32. https://doi.org/10.3346/jkms.2021.36.e207CrossRef

17.

Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H et al (2020) multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72(3):488–498. https://doi.org/10.1002/art.41105CrossRefPubMed

18.

Li L, Liu C, Wang Q, Wu C, Zhang Y, Cheng L et al (2020) Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis. J Clin Lab Anal 34:8. https://doi.org/10.1002/jcla.23307CrossRef

19.

Rogers M, Bethel A, Briscoe S (2020) Resources for forwards citation searching for implementation studies in dementia care: a case study comparing web of science and Scopus. Res Synth Methods 11(3):379–386. https://doi.org/10.1002/jrsm.1400CrossRefPubMed

20.

AlRyalat SAS, Malkawi LW, Momani SM (2019) Comparing bibliometric analysis using PubMed, Scopus, and web of science databases. J Vis Exp. https://doi.org/10.3791/58494CrossRefPubMed

21.

Falagas ME, Pitsouni EI, Malietzis GA, Pappas G (2008) Comparison of PubMed, Scopus, web of science, and Google scholar: strengths and weaknesses. FASEB J 22(2):338–342. https://doi.org/10.1096/fj.07-9492LSFCrossRefPubMed

22.

Kulkarni AV, Aziz B, Shams I, Busse JW (2009) Comparisons of citations in web of science, Scopus, and Google scholar for articles published in general medical journals. JAMA 302(10):1092–1096. https://doi.org/10.1001/jama.2009.1307CrossRefPubMed

23.

Kocyigit BF, Akyol A (2021) Bibliometric analysis of publication activity in the field of familial Mediterranean fever in 2010–2019: a Scopus-based study. Rheumatol Int 41(11):2015–2023. https://doi.org/10.1007/s00296-021-04988-zCrossRefPubMed

24.

Zhao X, Chen J, Pan Y, Feng H, Meng B, Meng Y (2019) A bibliometric analysis of the global research in ankylosing spondyloarthritis (2008–2017). Rheumatol Int 39(6):1091–1097. https://doi.org/10.1007/s00296-019-04308-6CrossRefPubMed

25.

Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63(3):713–721. https://doi.org/10.1002/art.30156CrossRefPubMedPubMedCentral

26.

Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468CrossRefPubMed

27.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis a randomized. Arthritis Rheum 65(2):314–324. https://doi.org/10.1002/art.37754CrossRefPubMedPubMedCentral

28.

Martynov I, Klima-Frysch J, Schoenberger J (2020) A scientometric analysis of neuroblastoma research. BMC Cancer 20:1. https://doi.org/10.1186/s12885-020-06974-3CrossRef

29.

Zhang K, Zhao J, Chu L, Jin Y, Cheng B, Xie G et al (2017) China’s growing contribution to sepsis research from 1984 to 2014 a bibliometric study. Medicine 96:25. https://doi.org/10.1097/MD.0000000000007275CrossRef

30.

Li S, Li W, Jiang W, He L, Peng Q, Wang G et al (2021) The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study. Front Pharmacol. https://doi.org/10.3389/fphar.2021.635654CrossRefPubMedPubMedCentral

31.

Xu X, Reed M (2021) The impact of internet access on research output-a cross-country study. Inf Econ Policy. https://doi.org/10.1016/j.infoecopol.2021.100914CrossRef

32.

Chinchilla-Rodriguez Z, Sugimoto CR, Lariviere V (2019) Follow the leader: on the relationship between leadership and scholarly impact in international collaborations. PLoS ONE 14:6. https://doi.org/10.1371/journal.pone.0218309CrossRef

33.

Butrous G (2008) International cooperation to promote advances in medicine. Ann Thorac Med 3(3):79–81. https://doi.org/10.4103/1817-1737.41913CrossRefPubMedPubMedCentral

34.

Man JP, Weinkauf JG, Tsang M, Sin DD (2004) Why do some countries publish more than others? an international comparison of research funding, English proficiency and publication output in highly ranked general medical journals. Eur J Epidemiol 19(8):811–817. https://doi.org/10.1023/b:ejep.0000036571.00320.b8CrossRefPubMed

35.

Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-mda5 antibodies bioclinical features pathogenesis and emerging therapies. Front Immunol. https://doi.org/10.3389/fimmu.2021.773352CrossRefPubMedPubMedCentral

36.

He L (2021) Recent research on myositis-specific autoantibodies in juvenile dermatomyositis. Chinese J Contemp Pedia 23(10):1064–1068. https://doi.org/10.7499/j.issn.1008-8830.2106011CrossRef

37.

Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A et al (2021) IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. J Intern Med 289(2):206–220. https://doi.org/10.1111/joim.13154CrossRefPubMed

38.

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34. https://doi.org/10.1016/j.jaad.2010.09.016CrossRefPubMedPubMedCentral

39.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma. Arthritis Rheum 65(11):2954–2962. https://doi.org/10.1002/art.38093CrossRefPubMedPubMedCentral

40.

Trallero-Araguas E, Angel Rodrigo-Pendas J, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M et al (2012) Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64(2):523–532. https://doi.org/10.1002/art.33379CrossRefPubMed

41.

Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T et al (2011) Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis A Multicenter Cross-sectional Study. Arch Dermatol 147(4):391–398. https://doi.org/10.1001/archdermatol.2011.52CrossRefPubMed

42.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78(7):988–995. https://doi.org/10.1136/annrheumdis-2018-215004CrossRefPubMed

43.

Damoiseaux J, Vulsteke J-B, Tseng C-W, Platteel ACM, Piette Y, Shovman O et al (2019) Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 18(3):293–305. https://doi.org/10.1016/j.autrev.2018.10.004CrossRefPubMed

44.

Kang EH, Ha Y-J, Lee YJ (2020) Autoantibody biomarkers in rheumatic diseases. Int J Mol Sci 21:4. https://doi.org/10.3390/ijms21041382CrossRef

45.

Luppi F, Sebastiani M, Silva M, Sverzellati N, Cavazza A, Salvarani C et al (2020) Interstitial lung disease in Sjogren’s syndrome: a clinical review. Clin Exp Rheumatol 38(4):S291–S300

46.

Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V (2018) The lung in rheumatoid arthritis focus on interstitial lung disease. Arthritis Rheumatol 70(10):1544–1554. https://doi.org/10.1002/art.40574CrossRefPubMed

47.

Aguilera-Pickens G, Abud-Mendoza C (2018) Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol Clin 14(5):294–300. https://doi.org/10.1016/j.reuma.2018.03.012CrossRefPubMed

48.

Long K, Danoff SK (2019) Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med 40(3):561–572. https://doi.org/10.1016/j.ccm.2019.05.004CrossRefPubMed

49.

Daniela De Filippo S-CE (2018) Bibliometric and altmetric analysis of three social science disciplines. Front Res Metr Anal. https://doi.org/10.3389/frma.2018.00034CrossRef

Titel: Bibliometric and altmetric analyses of publication activity in the field of idiopathic inflammatory myopathy in 2011–2021 based on web of science core collection databases
verfasst von: Mengxiang Li
Feng Yin
Youxian He
Xue Zhang
Hao Yu
Qiuyu Yang
Xintong Xie
Guangliang Wei
Huidong Chen
Chengsong He
Yue He
Jie Chen
Publikationsdatum: 27.09.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 6/2023
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-022-05211-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Burnout in South Asian rheumatologists in the COVID-19 pandemic: an online survey

Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review

Post-traumatic growth in adult patients with systemic lupus erythematosus: a cross-sectional study in China

The biopsychosocial impact of hypermobility spectrum disorders in adults: a scoping review

Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity